The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK

References

• Goadsby PJ, Lipton RB, Ferrari MD. Migraine–current understanding and treatment. N Engl J Med 2002;346:257-70
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edn. Cephalalgia 2004;24(1 Suppl):9-160
   Google Scholar
• Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30:599-609
   PubMed Web of Science ®Google Scholar
• Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology 2009;72:S3-S7
   PubMed Web of Science ®Google Scholar
• Blumenfeld A, Varon S, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011;31:301-15
   PubMed Web of Science ®Google Scholar
• Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2009;49:498-508
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network. Diagnosis and management of headache in adults: a national clinical guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network, 2008. p 1-81
   Google Scholar
• NHS Scotland. Neurology – Headache as a new complaint – Adult Patient Assessment Pathway – Migraine [database]. 2010. www.18weeks.scot.nhs.uk. Accessed September 26, 2012
   Google Scholar
• British Association for the Study of Headache. Guidelines for all healthcare professionals in the diagnosis and management of migraine, tension-type headache, cluster headache, and medication-overuse headache. 2010. http://217.174.249.183/upload/NS_BASH/2010_BASH_Guidelines.pdf. Accessed September 26, 2012
   Google Scholar
• Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008;71:559-66
   PubMed Web of Science ®Google Scholar
• Lafata JE, Tunceli O, Cerghet M, et al. The use of migraine preventive medications among patients with and without migraine headaches. Cephalalgia 2010;30:97-104
   PubMed Web of Science ®Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14
   PubMed Web of Science ®Google Scholar
• Dodick DW, Turkel CC, DeGryse R, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36
   PubMed Web of Science ®Google Scholar
• Manack AN, Buse DC, Lipton RB. Chronic migraine: epidemiology and disease burden. Curr Pain Headache Rep 2010;15:70-8
   Google Scholar
• Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998;38:295-302
   PubMed Web of Science ®Google Scholar
• Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res 2003;12:963-74
   PubMed Web of Science ®Google Scholar
• Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465-72
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE technology appraisal guidance 260. 2012. http://www.nice.org.uk/nicemedia/live/13776/59836/59836.pdf. Accessed September 7, 2012
   Google Scholar
• National Institute for Health and Clinical Excellence. Migraine (chronic) - botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine: final scope. 2011. http://www.nice.org.uk/nicemedia/live/13554/55946/55946.pdf. Accessed September 9, 2012
   Google Scholar
• Cady RK, Schreiber CP, Porter JA, et al. A multi-center double-blind pilot comparison of OnabotulinumtoxinA and Topiramate for the prophylactic treatment of chronic migraine. Headache 2011;51:21-32
   PubMed Web of Science ®Google Scholar
• Bloudek LM, Hansen RN, Liu L, et al. Health resource utilization and costs for migraineurs in Scotland. Presented at: International Society for Pharmacoecononics and Outcomes Research 16th Annual Conference; May 21–25, 2011; Baltimore, MD. Abstract PND32
   Google Scholar
• Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Office for National Statistics. Interim Life Tables, England, 1980–82 to 2008–10. UK: Office for National Statistics, 2011
   Google Scholar
• Rothrock JF, Andress-Rothrock D, Scalon C, et al. OnabotulinumtoxinA for the treatment of chronic migraine: long-term outcome. Presented at: American Headache Society (AHS) 53rd Annual Scientific Meeting; June 2–5, 2011; Washington, DC. Abstract P133
   Google Scholar
• Gillard PJ, Devine B, Varon SF, et al. Mapping from disease-specific measures to health-state utility values in individuals with migraine. Value Health 2012;15:485-94
   PubMed Web of Science ®Google Scholar
• British National Formulary. Botulinum toxin type A. 2012. http://www.bnf.org. Accessed September 11, 2012
   Google Scholar
• Curtis L. Unit costs of health and social care. Canterbury, UK: Personal Social Services Research Unit, University of Kent, 2011. http://www.pssru.ac.uk/archive/pdf/uc/uc2011/uc2011.pdf. Accessed September 11, 2012
   Google Scholar
• National Health Service. NHS reference costs 2009–2010. 2011. London, UK: Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_123459. Accessed September 12, 2012
   Google Scholar
• Health and Social Care Information Centre. Prescription costs analysis for England 2010. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england–2010. Accessed March 25, 2012
   Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. 2008. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed August 15, 2012
   Google Scholar
• Office for National Statistics. Annual survey of hours and earnings. 2010. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-238620. Accessed March 25, 2012
   Google Scholar
• Diener HC. Placebo in headache trials. Cephalalgia 2003;23:485-6
   Google Scholar
• Maglinte GA, Bloudek LM, Stokes ME, et al. Costs associated with lost productive time among working adults with chronic and episodic migraine in the United States and Canada. Presented at: 63rd American Academy of Neurology Annual Meeting; April 9–16, 2011; Honolulu, HI. Abstract P06.015
   Google Scholar
• Stewart WF, Woods GC, Manack A, et al. Employment and work impact of headache among episodic and chronic migraine sufferers: results of the American migraine prevalence and prevention (AMPP) study. Presented at: 14th Congress of the International Headache Society; September 10–13, 2009; Philadelphia, PA. Abstract PO119
   Google Scholar
• Allergan, Inc. Allergan comment on Appraisal Consultation Document: Botulinum toxin A for the prevention of headaches in adults with chronic migraine. 2012. UK: National Institute for Health and Clinical Excellence, http://www.nice.org.uk/nicemedia/live/13554/59149/59149.pdf. Accessed September 9, 2012
   Google Scholar